Integra LifeSciences Holdings Corporation's RSI is 33.35.
A number of other institutional investors have also recently bought and sold shares of the stock. American Century Companies Inc. boosted its position in Edwards Lifesciences Corp.by 83.1% in the second quarter.
BlackRock Income Trust, Inc.is a diversified, closed-end management investment company. Alps Advisors Inc. increased its position in shares of Edwards Lifesciences Corporation by 0.3% during the second quarter. Closing price generally refers to the last price at which a stock trades during a regular trading session. Analysts covering the shares have a consensus short-term price target of $56.54 on the equity. SG Americas Securities LLC now owns 4,294 shares of the life sciences company's stock valued at $181,000 after acquiring an additional 1,557 shares during the last quarter. M Holdings Securities Inc. now owns 4,132 shares of the medical research company's stock worth $389,000 after acquiring an additional 62 shares during the period. Ameriprise Financial Inc. boosted its position in Edwards Lifesciences Corp.by 62.3% in the second quarter. Veritable L.P. now owns 6,244 shares of the medical research company's stock worth $738,000 after acquiring an additional 71 shares during the period. The stock of Integra Lifesciences Holdings Corp (NASDAQ:IART) has "Hold" rating given on Friday, September 1 by RBC Capital Markets.
"EW's Chairman & CEO MUSSALLEM MICHAEL A Sell 32900 shares of the company at a price of $100.93 on 2017-10-30". The 50 day moving average went down by -6.332% and the 200 day average went down by -8.697%. According to a recent spotcheck, company Edwards Lifesciences Corporation (NYSE:EW) have been seen trading -11.57% away from the 50- day high.
Edwards Lifesciences Corporation (NYSE:EW) last posted its quarterly earnings data on Tuesday, October 24th. The business had revenue of $278.83 million for the quarter, compared to the consensus estimate of $286.00 million. During the same period in the previous year, the company earned $0.68 EPS. As of the latest earnings report the EPS was $3.30 and is estimated to be $3.75 for the current year with 211,158,000 shares presently outstanding. Raymond James upgraded the stock to "Outperform" rating in Wednesday, July 29 report. It is trading at $101.63 which is slightly below $110.17, the 50 day moving average and a bit lower than the 200 day moving average of $112.73. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The disclosure for this purchase can be found here. The stock has a market capitalization of $3.63 billion, a price-to-earnings ratio of 56.70 and a beta of 0.71. Riverhead Capital Mgmt Limited Liability Company holds 0.01% of its portfolio in Integra Lifesciences Holdings Corp (NASDAQ:IART) for 2,399 shares.
ILLEGAL ACTIVITY NOTICE: "Somewhat Positive Media Coverage Somewhat Unlikely to Affect Edwards Lifesciences Corporation (EW) Share Price" was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and worldwide copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2017/11/01/edwards-lifesciences-corporation-ew-holdings-trimmed-by-winslow-evans-crocker-inc.html.
EW has been the subject of several other research reports.
October 26 investment analysts at Morgan Stanley kept the stock rating at "Hold" and raised the price target from $58.00 to $115.00. (EW)-9 analysts issued Buy for the stock, 8 analysts gave Outperform rating, 4 think it's a Hold, 0 issued Underperform, while 1 analyst gave a Sell rating. Oppenheimer Holdings, Inc. reissued a "buy" rating on shares of Integra LifeSciences Holdings Corporation in a research note on Wednesday, July 26th. Finally, UBS AG reissued a "buy" rating and set a $57.00 target price on shares of Integra LifeSciences Holdings Corporation in a research note on Tuesday. The stock of Edwards Lifesciences Corp (NYSE:EW) has "Buy" rating given on Wednesday, October 11 by BMO Capital Markets. As per Wednesday, July 27, the company rating was maintained by Citigroup. Finally, Edwards Lifesciences Corporation's Return on Investment, a measure used to evaluate the efficiency of an investment, calculated by the return of an investment divided by the cost, stands at 16.50%. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. The Company's divisions include United States, Europe, Japan and Rest of World.
- Financial Watchlist of Activision Blizzard, Inc (NASDAQ:ATVI)
- Team Unhappy With Akshay Kumar?
- Lana Del Rey will retire Harvey Weinstein-inspired track 'Cola'
- Occidental Petroleum Corp (NYSE:OXY) Institutional Investors Sentiment Unchanged in 2017 Q2
- Moses, Ekong, Ajayi Make CAF Player of the Year Shortlist
- Devon Energy Corporation (NASDAQ:DVN) Expected To Report Earnings On Tuesday
- Uttar Pradesh NTPC blast: 20 killed, 100 injured, death toll may rise
- Iran to reopen border crossings with Iraq's Kurdish region
- Manufacturing PMI records slow growth in October
- Suspect in NY attack once cited near North Platte